{"id":25664,"date":"2026-02-26T18:47:13","date_gmt":"2026-02-26T18:47:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/25664\/"},"modified":"2026-02-26T18:47:13","modified_gmt":"2026-02-26T18:47:13","slug":"jim-cramer-recommends-eli-lilly-over-novo-nordisk-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/25664\/","title":{"rendered":"Jim Cramer Recommends Eli Lilly over Novo Nordisk"},"content":{"rendered":"\n

Novo Nordisk A\/S (NYSE:NVO<\/a>) is one of the stocks Jim Cramer commented on<\/a>. Answering a caller\u2019s question about the stock during the lightning round, Cramer said:<\/p>\n

Oh no, you don\u2019t want to be in Novo Nordisk. You want to be in Eli Lilly. Novo Nordisk is really good at cutting prices. Eli Lilly\u2019s great at making drugs.<\/p>\n

\"\" <\/p>\n

Photo by Adam Nowakowski<\/a> on Unsplash<\/a><\/p>\n

Novo Nordisk A\/S (NYSE:NVO) manufactures pharmaceuticals for chronic conditions, including diabetes, obesity, and rare blood or endocrine disorders. The company also produces some medical devices. Cramer mentioned the company during the February 4 episode and remarked:<\/p>\n

What went wrong at Novo Nordisk? Yesterday, the Danish drug maker behind Ozempic reported, and the stock plunged nearly 15% before sinking another 6% today. While the quarter was fine, the guidance, let\u2019s just say it was brutal. They\u2019re talking about a 5% to 13% sales hit this year, thanks to pricing pressures amid fierce competition for the GLP-1 business. It seems Eli Lilly\u2019s eating their lunch, even if it is a lunch that has no taste, an inevitable result of all GLPs.<\/p>\n

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/a>.<\/p>\n

READ NEXT: 30 Stocks That Should Double in 3 Years<\/a> and

Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Answering a caller\u2019s question about…\n","protected":false},"author":2,"featured_media":17570,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[12581,16712,276,16711,2961,272],"class_list":{"0":"post-25664","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-adam-nowakowski","9":"tag-chronic-conditions","10":"tag-eli-lilly","11":"tag-endocrine-disorders","12":"tag-jim-cramer","13":"tag-novo-nordisk"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/25664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=25664"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/25664\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/17570"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=25664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=25664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=25664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}